In light of this, our current study suggests that immune pressure imposed by immunotherapy drives the selective enrichment of pre-existing E2F1+ tumor cells within the parental population, which in turn upregulate HMGCR expression and promote ferroptosis resistance. This evidence concerns the gene E2F1 and neoplasm.